modafinil
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methamphetamine Addiction
Conditions
Methamphetamine Addiction
Trial Timeline
Jan 1, 2008 → Jun 1, 2011
NCT ID
NCT00538655About modafinil
modafinil is a phase 2 stage product being developed by Pacific Biosciences for Methamphetamine Addiction. The current trial status is completed. This product is registered under clinical trial identifier NCT00538655. Target conditions include Methamphetamine Addiction.
What happened to similar drugs?
1 of 1 similar drugs in Methamphetamine Addiction were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01354470 | Phase 2 | Completed |
| NCT00630097 | Phase 2 | UNKNOWN |
| NCT00538655 | Phase 2 | Completed |
Competing Products
6 competing products in Methamphetamine Addiction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CPP-109 vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2 | 21 |
| A single oral 5 mg of duterium labeled methamphetamine | Pacific Biosciences | Approved | 25 |
| Dextroamphetamine + Placebo | Pacific Biosciences | Phase 2 | 25 |
| Naltrexone | Pacific Biosciences | Phase 2 | 25 |
| Modafinil | Pacific Biosciences | Phase 2 | 25 |
| Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet | MediciNova | Phase 1 | 19 |